Pleiotropic effects of levosimendan on the heart and other organs

<p>Levosimendan is a cardiotonic drug with vasodilating properties. The main mechanisms of its action include increased sensitivity of contractile proteins in cardiomyocytes to calcium and its ability to open ATP-dependent potassium channels in the smooth muscles of the vascular walls. In accordance with the recommendations of the European Society of Cardiology, the main indication for drug use is the treatment of acute decompensated chronic heart failure. Since the first use of the drug (15 years ago), a number of additional, pleiotropic effects have been discovered, which not only affect the myocardium (ischemia and remodeling), but might potentiate organoprotective processes “outside” of the cardiovascular system. The experimental and clinical studies have allowed to identify some positive mechanisms beneficially influencing the function of the lungs, kidneys, liver, gastrointestinal tract, central nervous system, as well as the sepsis and inflammation processes. This paper summarizes the existing research and evidence of pleiotropic effects of levosimendan and outlines some potential new areas of its clinical application.<br /><br />Received 3 April 2017. Accepted 30 May 2017.</p><p><strong>Funding:</strong> The study did not have sponsorship.<br /><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p>

INVESTIGATIONS OF THE INFLUENCE OF SUFAN ON MYOCARDIAL METABOLISM IN CASES OF EXPERIMENTAL HEART FAILURE

This article presents the results of an influence by the new non-glycoside structure, metabolic cardiotonic drug “sufan” on the energetic metabolism and oxidative homeostasis indicators—in myocardium, brain, and spleen of intact rats and rats with adriamycin-induced heart failure. It was established that sufan increased the coefficient of oxidative/reduced forms of nicotinamide coenzymes, reduced the adriamycin, causing deterioration of the energetic metabolism and the pro-oxidative-anti-oxidative homeostasis. The use of the non-glycoside structure cardiotonic drug, sufan, is recommended in order to prevent cardiotoxic effects of the anthracycline antibiotics.